

Remarks

The Amendment

Applicants have deleted old Claims 1, 2 and 4-20 and added new Claim 22. New Claim 21 is based on old enumerated embodiment 27, page 313, lines 13-16. It is recited as an independent claim based on old enumerated embodiment 3, page 308.

Applicants respectfully draw the Examiner's attention to Claim 13 of copending U.S. Patent Application Serial No. 08/580,567 (Attorney Docket 205.2), also under Examination by this Examiner. In particular Applicants refer the Examiner to the definitions of W₆ in the respective applications. Should the Examiner determine that double patenting exists between new Claim 21 and Claim 13 of the '567 application, Applicants are willing to provide a terminal disclaimer to obviate that rejection.

Rejection Under 35 U.S.C. §102(b)

The Office has rejected old Claims 1, 2 and 4-20, over Meindl, et al. Applicants believe that this rejection is rendered moot by the present amendment because, *inter alia*, Meindl is directed to heterocycles whereas new Claim 21 is directed to carbocycles.

Request for a Telephonic Interview

If the Examiner deems it useful, Applicants request, at the Examiner's convenience, a telephonic interview with Mark Bosse at (650) 572-6569 for the purpose of expediting the allowance of the present Application.

Conclusion

Applicants have canceled all pending claims and added new Claim 21.

Respectfully submitted,

Mark L. Bosse

Mark L. Bosse, Reg. No. 35,071

Gilead Sciences, Inc.

333 Lakeside Drive

Foster City, CA 94404

Telephone: (650) 572-6569

Facsimile: (650) 573-4899

Dated: 03/03/98